0NZY.L - Eckert & Ziegler Strahlen- und Medizintechnik AG

LSE - LSE Delayed price. Currency in EUR
39.73
+1.73 (+4.56%)
At close: 06:17PM BST
Stock chart is not supported by your current browser
Previous close37.99
Open39.24
Bid0.00 x 0
Ask0.00 x 0
Day's range39.24 - 39.50
52-week range39.24 - 39.50
Volume2,269
Avg. volumeN/A
Market cap2.033M
Beta (5Y monthly)N/A
PE ratio (TTM)0.30
EPS (TTM)1.30
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Eckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA

    EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Conference/MiscellaneousEckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA 30.05.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.BOSTON, Mass., May 30, 2023 – By organizing the first Boston Radionuclide Theranostics Forum and bringing together numerous renowned experts in Boston, Mass., Eckert & Ziegler underscores its leading position in the field of rad

  • EQS Group

    ​​​​​​​Reorganization in the Executive Board of Eckert & Ziegler

    EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Personnel​​​​​​​Reorganization in the Executive Board of Eckert & Ziegler 15.05.2023 / 09:27 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, May 15, 2023. The Supervisory Board of Eckert & Ziegler AG has now formally approved the reorganization of the Executive Board already announced in December 2022. Accordingly, the founder and Chairman of the Executive Board, Dr. Andreas Eckert, an

  • Simply Wall St.

    Eckert & Ziegler Strahlen- und Medizintechnik First Quarter 2023 Earnings: EPS: €0.23 (vs €0.32 in 1Q 2022)

    Eckert & Ziegler Strahlen- und Medizintechnik ( ETR:EUZ ) First Quarter 2023 Results Key Financial Results Revenue...

  • EQS Group

    Eckert & Ziegler with Strong Sales Growth in the First Quarter of 2023

    EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Quarter ResultsEckert & Ziegler with Strong Sales Growth in the First Quarter of 2023 11.05.2023 / 07:45 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 11 May 2023. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 16% to EUR 57.9 million in the first quarter of 2023. Net income amounted to EUR 4.7 million or EUR 0.23 per share and was

  • EQS Group

    Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate

    EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): AllianceEckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate 08.05.2023 / 11:15 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 8 May 2023 – Following clinical investigations of hypertension specialists in the Netherlands, France, the United States, and China, the

  • EQS Group

    Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance

    Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Quarter ResultsEckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance25-Apr-2023 / 17:59 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Berlin, April 25, 2023. A

  • EQS Group

    Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177

    EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): MiscellaneousEckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177 20.04.2023 / 10:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 20 April 2023 - Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), has received the manufacturing authorization for Lutetium-177 (non-carrier-added L

  • EQS Group

    Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site

    EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): ExpansionEckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site 12.04.2023 / 15:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 12 April 2023 – Eckert & Ziegler’s fully owned subsidiary Qi Kang Medical Technology Ltd. (QKM) has recently received the authorization for its Environmental Impact Assessment (EIA) from the Department of Ecology and Environment of Ji

  • EQS Group

    Eckert & Ziegler to Supply POINT Biopharma with Actinium-225

    EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Contract/Incoming OrdersEckert & Ziegler to Supply POINT Biopharma with Actinium-225 04.04.2023 / 14:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, Germany and Indianapolis, Indiana, USA – 4 April 2023 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (“POINT”, NASDAQ: PNT) have signed an agreement on the supply of Actinium-225 (non-carr

  • EQS Group

    ​​​​​Eckert & Ziegler: Successful fiscal year 2022

    EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Annual Results/Forecast​​​​​Eckert & Ziegler: Successful fiscal year 2022 30.03.2023 / 07:45 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 30 March 2023 - Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) achieved sales of € 222.3 million in FY 2022. Compared to the previous year, sales increased by € 41.9 million or 23%. Net income reached € 29.3 million, thus increasing by nearly 20%

  • EQS Group

    ​​​​​​​Eckert & Ziegler Plans Change of Legal Form to European Stock Corporation (SE)

    EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Miscellaneous​​​​​​​Eckert & Ziegler Plans Change of Legal Form to European Stock Corporation (SE) 24.03.2023 / 16:40 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 24 March 2023. The Executive Board and Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) have decided to prepare the conversion of the company into a European Company (Societas Europaea, SE) by changing

  • EQS Group

    Eckert & Ziegler with Unchanged Dividend Proposal

    EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Dividend/Annual ResultsEckert & Ziegler with Unchanged Dividend Proposal 23.03.2023 / 18:33 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 23 March 2023 - Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) closed FY 2022 with sales of 222.3 million EUR. Net income for the year rose by around 20% compared to the previous year's figure adjusted for special effects and reached 29.3 million

  • EQS Group

    Eckert & Ziegler Submits Drug Master File for Lu-177 n.c.a.

    EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): MiscellaneousEckert & Ziegler Submits Drug Master File for Lu-177 n.c.a. 03.03.2023 / 10:15 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 3 March 2023. Eckert & Ziegler (ISIN DE0005659700, SDAX) has successfully submitted a Type II Drug Master File (DMF) with the U.S. Food and Drug Administration for lutetium (177Lu) chloride solution (containing no-carrier-added radioisotope Lutetiu

  • EQS Group

    Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting

    EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Alliance/StudyLausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting 01.02.2023 / 10:35 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 01.02.2023. The Lausanne University Hospital (CHUV) has reported the initial dosing of a patient in a phase II clinical study investigating the sensitivity of PENTIXAFOR (Boclatixafotide) in a cardiovascular and inflamma

  • EQS Group

    Eckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures

    Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Preliminary ResultsEckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures17-Jan-2023 / 12:47 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Berlin, 17 January 2023. According to preliminary, unaudited figures, Eckert &

  • EQS Group

    Change in the Supervisory Board of Eckert & Ziegler AG

    EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): PersonnelChange in the Supervisory Board of Eckert & Ziegler AG 20.12.2022 / 18:31 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 20.12.2022. Eckert Wagniskapital und Frühphasenfinanzierung GmbH has appointed radiation physicist Paola Eckert-Palvarini as its new representative on the Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700, SDAX). She replaces sinologist Jutta Ludw

  • EQS Group

    Changes in the Management Board of Eckert & Ziegler

    Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): PersonnelChanges in the Management Board of Eckert & Ziegler19-Dec-2022 / 13:29 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Berlin, 19.12.2022. The founder and CEO of Eckert & Ziegler AG (ISIN DE0005659700, SDAX), Dr. Andreas Eckert, today gave notice to

  • EQS Group

    Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR

    Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): StudyEckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR25-Nov-2022 / 15:36 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Berlin, 25 November 2022. PENTIXAPHARM GmbH, a 100% subsidiary of Eckert & Ziegler AG (ISIN DE0005659700, SDAX),

  • EQS Group

    ​​​​​​​Eckert & Ziegler: Nine-Month Figures Show Strong Sales Growth

    EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): 9 Month figures​​​​​​​Eckert & Ziegler: Nine-Month Figures Show Strong Sales Growth 08.11.2022 / 07:45 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 8 November 2022. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) increased sales by 25% to EUR 164.0 million in the first nine months of 2022. Net income of EUR 23.3 million was EUR 5.8 million lower than in th

  • EQS Group

    First CNS Lymphoma Patient Imaged with PentixaFor in Phase 2 Trial

    EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): StudyFirst CNS Lymphoma Patient Imaged with PentixaFor in Phase 2 Trial 27.10.2022 / 10:59 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin/Aalborg, 27 October 2022. The University Hospital Aalborg (Denmark) yesterday has imaged the first patient with Eckert and Ziegler’s Gallium (68Ga) boclatixafortide (PENTIXAFOR) in an international phase 2 trial. Code named PTF202, the clinical exami

  • EQS Group

    Eckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement

    EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Contract/Incoming OrdersEckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement 13.10.2022 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 13 October 2022. Eckert & Ziegler (ISIN DE0005659700, SDAX) and Alpha-9 Theranostics Inc. (Alpha-9), a radiopharmaceutical company with offices in Vancouver and Boston, have signed an agreement for the preferred supply

  • EQS Group

    Eckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility

    EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Incoming OrdersEckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility 11.10.2022 / 14:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, Germany and BELOIT, Wis., 11 October 2022 - Eckert & Ziegler Isotope Technologies Dresden (ITD), a specialist for radiopharmaceutical plant engineering and fully owned subsidiary of Ec

  • EQS Group

    ​​​​​​​Eckert & Ziegler with Successful First Half of 2022

    DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Half Year Results/Quarterly / Interim Statement​​​​​​​Eckert & Ziegler with Successful First Half of 2022 11.08.2022 / 07:45 The issuer is solely responsible for the content of this announcement.Berlin, 11 August 2022. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) increased sales by 19% to EUR 106.8 million in the first half of the year. At EUR 15.4 million, net income was down on the same per

  • EQS Group

    Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures

    DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): ContractEckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures 04.08.2022 / 10:07 The issuer is solely responsible for the content of this announcement.BERLIN, GERMANY, August 04, 2022 – Myelo Therapeutics GmbH, an Affiliate of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) and member of a pan-European consortium

  • EQS Group

    Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter

    Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Half Year ResultsEckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter27-Jul-2022 / 12:53 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Insider information pursuant to Article 17 MA Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2